Recalls / Class II

Class IID-0843-2022

Product

Losartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/12.5 mg a) 30-count bottles (NDC# 68180-216-06) b) 90-count bottles (NDC# 68180-216-09), Rx Only, Manufactured By: Lupin Limited, Pithampur, India, MFG For: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, USA

Brand name

Losartan Potassium And Hydrochlorothiazide

Generic name

Losartan Potassium And Hydrochlorothiazide

Active ingredients

Hydrochlorothiazide, Losartan Potassium

Route

Oral

NDCs

68180-215, 68180-216, 68180-217

FDA application

ANDA078245

Affected lot / code info

Lot # H001878 6/30/2022 68180-216-06 H002178 7/31/2022 68180-216-06 H002626 9/30/2022 68180-216-06 H102149 9/30/2023 68180-216-06 H001600 5/31/2022 68180-216-09 H001601 5/1/2022 68180-216-09 H001625 5/31/2022 68180-216-09 H001626 5/31/2022 68180-216-09 H001794 6/30/2022 68180-216-09 H001795 6/30/2022 68180-216-09 H001796 6/30/2022 68180-216-09 H001797 6/30/2022 68180-216-09 H001879 6/30/2022 68180-216-09 H001880 6/30/2022 68180-216-09 H001881 6/30/2022 68180-216-09 H001942 6/30/2022 68180-216-09 H001943 6/30/2022 68180-216-09 H001944 6/30/2022 68180-216-09 H001945 6/30/2022 68180-216-09 H001946 6/30/2022 68180-216-09 H002179 7/31/2022 68180-216-09 H002180 7/31/2022 68180-216-09 H002181 8/31/2022 68180-216-09 H002182 8/31/2022 68180-216-09 H002183 8/31/2022 68180-216-09 H002237 8/31/2022 68180-216-09 H002238 8/31/2022 68180-216-09 H002239 8/31/2022 68180-216-09 H002240 8/31/2022 68180-216-09 H002241 8/31/2022 68180-216-09 H002627 9/30/2022 68180-216-09 H002628 9/30/2022 68180-216-09 H002629 9/30/2022 68180-216-09 H002630 9/30/2022 68180-216-09 H002631 9/30/2022 68180-216-09 H002979 11/30/2022 68180-216-09 H002980 11/30/2022 68180-216-09 H002981 11/30/2022 68180-216-09 H002982 11/30/2022 68180-216-09 H002983 11/30/2022 68180-216-09 H100112 12/31/2022 68180-216-09 H100113 12/31/2022 68180-216-09 H100114 12/31/2022 68180-216-09 H100115 12/31/2022 68180-216-09 H100116 12/31/2022 68180-216-09 H100156 12/31/2022 68180-216-09 H100157 12/31/2022 68180-216-09 H100622 2/28/2023 68180-216-09 H100623 2/28/2023 68180-216-09 H100624 2/28/2023 68180-216-09 H100625 2/28/2023 68180-216-09 H100626 2/28/2023 68180-216-09 H100627 2/28/2023 68180-216-09 H100628 2/28/2023 68180-216-09 H100629 2/28/2023 68180-216-09 H100939 4/30/2023 68180-216-09 H100940 4/30/2023 68180-216-09 H100941 4/30/2023 68180-216-09 H100942 4/30/2023 68180-216-09 H100943 4/30/2023 68180-216-09 H101094 5/31/2023 68180-216-09 H101095 5/31/2023 68180-216-09 H101096 5/31/2023 68180-216-09 H101097 5/31/2023 68180-216-09 H101098 5/31/2023 68180-216-09 H101151 5/31/2023 68180-216-09 H101152 5/31/2023 68180-216-09 H101290 5/31/2023 68180-216-09 H101291 5/31/2023 68180-216-09 H101292 5/31/2023 68180-216-09 H101293 5/31/2023 68180-216-09 H101323 5/31/2023 68180-216-09 H101324 5/31/2023 68180-216-09 H101823 7/31/2023 68180-216-09 H101824 7/31/2023 68180-216-09 H101825 7/31/2023 68180-216-09 H101853 8/31/2023 68180-216-09 H101854 8/31/2023 68180-216-09 H101855 8/31/2023 68180-216-09 H101856 8/31/2023 68180-216-09 H102127 9/30/2023 68180-216-09 H102128 9/30/2023 68180-216-09 H102129 9/30/2023 68180-216-09 H102130 9/30/2023 68180-216-09 H102150 9/30/2023 68180-216-09 H102151 9/30/2023 68180-216-09 H102152 9/30/2023 68180-216-09 H102153 9/30/2023 68180-216-09 H102154 9/30/2023 68180-216-09 H102155 9/30/2023 68180-216-09 H102201 9/30/2023 68180-216-09 H102223 9/30/2023 68180-216-09 H102268 9/30/2023 68180-216-09 H102269 9/30/2023 68180-216-09 H102270 9/30/2023 68180-216-09 H102271 9/30/2023 68180-216-09

Why it was recalled

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Recalling firm

Firm

Lupin Pharmaceuticals Inc.

Manufacturer

Lupin Pharmaceuticals, Inc.

Notification channel

Letter

Type

Voluntary: Firm initiated

Address

Harborplace Tower, 111 S Calvert St Fl 21st, Baltimore, Maryland 21202-6174

Distribution

Quantity

2,361,924 bottles

Distribution pattern

Product was distributed nationwide

Timeline

Recall initiated

2022-03-31

FDA classified

2022-05-03

Posted by FDA

2022-05-11

Terminated

2023-05-22

Status

Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0843-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.